Western Pacific Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Western Pacific Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$157K	Hold	3,300	–	–	0.16%	70
2025 Q4	$173K	Hold	3,300	–	–	0.17%	66
2025 Q3	$214K	Buy	3,300 +2,800	+560%	+$161K	0.21%	60
2025 Q2	$24.3K	Sell	500 -500	-50%	-$19.4K	0.02%	151
2025 Q1	$34K	Hold	1,000	–	–	0.03%	142
2024 Q4	$39.4K	Buy	1,000 +500	+100%	+$23.6K	0.03%	146
2024 Q3	$23.5K	Buy	+500	New	+$25.4K	0.02%	186

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Western Pacific Wealth Management's CRSP Position: Q1 2026 in Review

Western Pacific Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 3,300 shares worth $157K. The position accounts for 0.16% of the portfolio, ranked #70.

Western Pacific Wealth Management first reported a position in CRSP in Q3 2024 and has held it in 7 quarters since. The position peaked at $214K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Western Pacific Wealth Management held 3,300 shares of CRISPR Therapeutics worth $157K as of Q1 2026.
Western Pacific Wealth Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up 0.16% of Western Pacific Wealth Management's portfolio in Q1 2026, its #70 holding.
Western Pacific Wealth Management first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 7 quarters since.
Western Pacific Wealth Management's CRISPR Therapeutics position peaked at $214K in Q3 2025.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Western Pacific Wealth Management's 13F filing for Q1 2026, filed 17 Apr 2026.